Ignite Creation Date:
2025-12-25 @ 2:43 AM
Ignite Modification Date:
2026-01-09 @ 12:57 AM
Study NCT ID:
NCT01951833
Status:
WITHDRAWN
Last Update Posted:
2015-01-15
First Post:
2013-03-14
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Long Term Significance (Survival) of LCI in Patients With Cystic Fibrosis
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003550', 'term': 'Cystic Fibrosis'}], 'ancestors': [{'id': 'D010182', 'term': 'Pancreatic Diseases'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D009358', 'term': 'Congenital, Hereditary, and Neonatal Diseases and Abnormalities'}, {'id': 'D007232', 'term': 'Infant, Newborn, Diseases'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'CASE_CONTROL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 0}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'WITHDRAWN', 'startDateStruct': {'date': '2013-01'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2013-11', 'completionDateStruct': {'date': '2017-05', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2015-01-14', 'studyFirstSubmitDate': '2013-03-14', 'studyFirstSubmitQcDate': '2013-09-24', 'lastUpdatePostDateStruct': {'date': '2015-01-15', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2013-09-27', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2015-05', 'type': 'ESTIMATED'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Symptom score', 'timeFrame': '1 week, 3 months', 'description': 'Symptom score is calculated at 1 week and 3 months to ensure a stable disease of the patient to avoid bias during the calculation of LCI repeatability.'}], 'primaryOutcomes': [{'measure': 'Lung Clearance Index (Predictive value and change of)', 'timeFrame': 'Baseline, 1 week, 3 months and 2 years', 'description': 'Evaluation of LCI is repeated at 1 week and 3 months to assess short and intermediate repeatability.\n\nLCI and spirometry will be repeated after 22-24 months after the baseline measurement. This will allow to evaluate tracking of LCI as well as FEV1 % predicted in the total patient cohort as well as in the patients with FEV1 above 80% predicted.'}], 'secondaryOutcomes': [{'measure': 'FEV1 (Predictive value and change of)', 'timeFrame': 'baseline and 2 years', 'description': 'LCI and spirometry will be repeated after 22-24 months after the baseline measurement. This will allow to evaluate tracking of LCI as well as FEV1 % predicted in the total patient cohort as well as in the patients with FEV1 above 80% predicted.'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['Lung clearance index (LCI)'], 'conditions': ['Cystic Fibrosis (CF)']}, 'descriptionModule': {'briefSummary': "The current dream in CF research is to discover safe drugs that correct the basic defect and prevent lung disease, allowing patients without significant lung damage to live nearly normal lives with a dramatic increase in life expectancy and without the burden of current treatment. The compound VX-770 (Ivacaftor Ò) is hoped to be the first milestone along this way. Progression of lung disease is now so gradual in many centres that sensitive indicators of early lung disease (small airways disease) are critically needed to assess the effects of such new treatments. In this context, assessment of ventilation inhomogeneity by the measurement called Lung clearance index (LCI) seems to be the most promising tool. However, to get approval by health authorities, new measures used in drug evaluation need to fulfill strict criteria. For LCI, the investigators still need to prove its long term significance: How well does the LCI measurement predict the long term lung disease course? Therefore, in this study the investigators want to measure LCI at baseline in a large patient cohort and establish how well it predicts the patients' disease course over the next 2 years.", 'detailedDescription': 'Patients with CF ( 6 years and older and FEV1 above 40% predicted) will be invited to participate in this prospective non interventional study in 2 CF centers ( UCL and UZ Leuven). Jointly we take care of more than 40 % of the Belgian CF population. Median FEV1 of children (6 - \\<18 y, n \\>120) from these CTN centers is high ( around 100% pred), defining a study group of great interest in the current context.\n\nTo assess the predictive value of LCI over 2 years, the time to next pulmonary exacerbation will be evaluated in the entire cohort. To assess the predictive value of LCI over 2 years, the time to next pulmonary exacerbation will be evaluated in the entire cohort.\n\nRepeat LCI measurements will be done at subsequent patient visits.\n\n2 devices measuring the LCI will be tested and compared : Ecomedics and NDD.\n\nLCI and spirometry will be measured in 120 healthy Belgian children and young adults. These subjects must be free of respiratory symptoms for at least two weeks and will not have any chronic or recurrent chest problem.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '6 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'Patients with Cystic Fibrosis ( 6 years and older and FEV1 above 40% predicted) will be invited to participate in this prospective non interventional study in 2 CF centers (UCL and UZ Leuven)', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* FEV1(% predicted) \\> 40%\n\nExclusion Criteria:\n\n* FEV1(% predicted) \\< 40%\n* Exacerbation during baseline measurement'}, 'identificationModule': {'nctId': 'NCT01951833', 'briefTitle': 'Long Term Significance (Survival) of LCI in Patients With Cystic Fibrosis', 'organization': {'class': 'OTHER', 'fullName': 'University Hospital St Luc, Brussels'}, 'officialTitle': 'Does Lung Clearance Index (LCI) Predict the Future Lung Disease Course in Patients With Cystic Fibrosis', 'orgStudyIdInfo': {'id': 'LCI-01-St-Luc'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Cystic fibrosis (Ecomedics vs NDD)', 'description': 'No treatment, observational', 'interventionNames': ['Device: EasyOne Pro and Ecomedics']}, {'label': 'Healthy (Ecomedics vs NDD)', 'description': 'Free of respiratory symptoms for at least two weeks and will not have any chronic or recurrent chest problem.\n\nNo treatment, observational', 'interventionNames': ['Device: EasyOne Pro and Ecomedics']}], 'interventions': [{'name': 'EasyOne Pro and Ecomedics', 'type': 'DEVICE', 'description': 'LCI will be assessed with 2 different devices : EasyOne Pro and Ecomedics', 'armGroupLabels': ['Cystic fibrosis (Ecomedics vs NDD)', 'Healthy (Ecomedics vs NDD)']}]}, 'contactsLocationsModule': {'locations': [{'zip': '1200', 'city': 'Woluwé-Saint-Lambert', 'state': 'Brussels Capital', 'country': 'Belgium', 'facility': 'Cliniques Universitaires Saint-Luc (UCL)'}], 'overallOfficials': [{'name': 'Lebecque Patrick, PhD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Cliniques universitaires Saint-Luc- Université Catholique de Louvain'}, {'name': 'Poncin William', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Cliniques universitaires Saint-Luc- Université Catholique de Louvain'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'University Hospital St Luc, Brussels', 'class': 'OTHER'}, 'collaborators': [{'name': 'KU Leuven', 'class': 'OTHER'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Physiotherapist', 'investigatorFullName': 'Poncin William', 'investigatorAffiliation': 'University Hospital St Luc, Brussels'}}}}